Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Sep 30, 2024 | (FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | (Q2)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 1.48%44.92B | 8.98%187.41B | 4.99%46.53B | -9.87%43.71B | 9.00%48.12B | 11.23%44.27B | 16.95%171.97B | 18.66%44.32B | 25.92%48.49B | 17.53%44.14B |
Cost of revenue | -2.59%13.6B | -0.58%57.68B | 10.32%14.65B | 2.18%15.06B | -5.17%14.32B | -4.14%13.96B | 11.76%58.01B | -4.44%13.28B | 11.96%14.74B | 14.86%15.1B |
Gross profit | 3.35%31.32B | 13.84%129.73B | 2.71%31.88B | -15.13%28.65B | 16.38%33.79B | 20.11%30.31B | 19.77%113.96B | 32.35%31.04B | 33.17%33.75B | 18.97%29.04B |
Operating expense | 4.43%26.98B | 15.04%112.24B | 9.65%27.19B | -18.78%23.37B | 13.85%30.45B | 14.01%25.83B | -1.30%97.57B | 10.31%24.8B | 1.83%28.77B | -1.07%26.74B |
Selling and administrative expenses | 6.38%27.22B | 14.00%110.86B | 5.47%26.45B | -19.08%23.46B | 14.40%29.83B | 13.06%25.59B | --97.25B | --25.08B | --28.99B | --26.07B |
-General and administrative expense | 6.38%27.22B | 14.00%110.86B | 5.47%26.45B | -19.08%23.46B | 14.40%29.83B | 13.06%25.59B | --97.25B | --25.08B | --28.99B | --26.07B |
Other operating expenses | -32.37%303M | 150.44%1.98B | 883.78%870M | -29.41%24M | -13.26%628M | 192.81%448M | --791M | ---111M | --34M | --724M |
Total other operating income | 164.11%552M | 27.78%598M | -23.84%131M | -56.28%108M | -81.82%10M | 58.33%209M | --468M | --172M | --247M | --55M |
Operating profit | -2.93%4.35B | 6.71%17.49B | -24.90%4.69B | 5.97%5.28B | 45.84%3.34B | 73.70%4.48B | 540.96%16.39B | 543.09%6.24B | 271.04%4.98B | 187.39%2.29B |
Net non-operating interest income (expenses) | 1,137.00%1.24B | 4,937.50%403M | 155.36%143M | -108.93%-5M | 3,366.67%104M | 317.39%100M | 108.89%8M | 411.11%56M | 800.00%56M | 113.04%3M |
Non-operating interest income | 525.81%1.36B | 77.84%891M | 40.64%263M | -27.89%137M | 93.81%219M | 244.44%217M | 902.00%501M | 1,235.71%187M | 691.67%190M | 1,514.29%113M |
Non-operating interest expense | 3.42%121M | -1.01%488M | -8.40%120M | 5.97%142M | 4.55%115M | 7.34%117M | 282.17%493M | 309.38%131M | 318.75%134M | 266.67%110M |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | ||||||||||
Other non-operating income (expenses) | ||||||||||
Income before tax | 22.00%5.58B | 9.13%17.89B | -23.30%4.83B | 4.67%5.27B | 50.17%3.45B | 80.84%4.58B | 510.13%16.39B | 621.90%6.3B | 268.00%5.04B | 184.85%2.3B |
Income tax | 44.55%2.55B | 32.49%4.43B | 103.41%83M | 137.47%1.99B | -3.42%1.75B | -10.83%1.76B | -8.13%3.35B | -381.81%-2.43B | -55.66%838M | 36,320.00%1.81B |
Net income | 7.89%3.04B | 3.14%13.46B | -45.63%4.75B | -21.87%3.28B | 250.31%1.7B | 407.03%2.81B | 270.76%13.05B | 96,866.67%8.73B | 185.86%4.2B | 117.95%485M |
Net income continuous operations | 7.89%3.04B | 3.14%13.46B | -45.63%4.75B | -21.87%3.28B | 250.31%1.7B | 407.03%2.81B | 270.78%13.05B | 96,866.67%8.73B | 185.88%4.2B | 117.96%485M |
Noncontrolling interests | 3,300.00%102M | 90.91%-6M | 23.33%37M | 616.67%31M | 24.53%-40M | 104.05%3M | 5.71%-66M | 123.26%30M | -106.52%-6M | 42.39%-53M |
Net income attributable to the company | 4.34%2.93B | 2.65%13.46B | -45.88%4.71B | -22.72%3.25B | 223.23%1.74B | 346.90%2.81B | 273.25%13.11B | 6,156.83%8.7B | 184.40%4.2B | 120.62%538M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 4.34%2.93B | 2.65%13.46B | -45.88%4.71B | -22.72%3.25B | 223.23%1.74B | 346.90%2.81B | 273.25%13.11B | 6,156.83%8.7B | 184.40%4.2B | 120.62%538M |
Gross dividend payment | ||||||||||
Basic earnings per share | 3.65%17.9 | 1.48%82.48 | -46.56%28.79 | -21.83%20.12 | 219.46%10.67 | 341.69%17.27 | 271.69%81.28 | 5,692.47%53.87 | 182.61%25.74 | 120.42%3.34 |
Diluted earnings per share | 5.44%17.44 | 1.80%79.01 | -45.52%27.6 | -19.79%19.78 | 209.39%10.21 | 328.50%16.54 | 263.94%77.61 | 5,761.03%50.66 | 179.14%24.66 | 120.17%3.3 |
Dividend per share | ||||||||||
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |